 |
answer text |
<p>The sector’s Life Science Industrial Strategy, authored by Professor Sir John Bell,
made recommendations to government in support of the vision for the UK to be a global
hub that makes the UK the home of clinical research and medical innovation. The two
Life Sciences Sector Deals are collaborative endeavours across government, academia,
charities and industry to deliver on this bold vision.</p><p>The two Deals include
significant joint investment from government and the sector to support research and
development, both academic and commercial, to ensure the UK remains at the forefront
of global drug development.</p><p>The UK has a track record of supporting university
spin out companies, with the goal of translating innovative research into commercial
successes and ultimately treatments that will benefit patients. Catalyst programmes,
including Innovate UK and the Medical Research Council’s Biomedical Catalyst aim to
de-risk innovative science and commercialise ideas arising out of academia and industry,
helping UK SMEs to develop into competitive and sustainable organisations.</p><p>The
Government recently announced further support for genomics as part of my rt. hon.
Friend Mr Chancellor of the Exchequer’s Spring Statement. The announcement featured
a £45 million investment for increasing the European Bioinformatics Institute’s computing
and storage capacity which underpins much of the UK’s genomics research work, including
UK Biobank. This announcement supports the boosting the UK’s genomics sector, which
is a key commitment in our second Life Sciences Sector Deal.</p>
|
|
